Japanese Drug Makers Seen Sitting Out M&A Flurry

Japan's pharmaceutical industry is a notable absentee in the flurry of consolidation among the global players. Instead of major acquisitions being made by foreign competitors, Japanese drug makers appear satisfied to concentrate on minor acquisitions designed to give them strengths they still lack in their pipelines. Analysts still expect Japanese drug makers look overseas for acquisitions or partnerships in an effort to spread their risk beyond the Japanese market expected to grow stagnant. Possible targets include biotech ventures. (Click here for more - a subscription may be required